Shaanxi Micot says Phase II trial database lock completed for stroke drug candidate MT200605

• Shaanxi Micot Pharmaceutical Technology reported a database lock for its Phase II China trial of MT200605 in acute ischemic stroke.
• Results have not been presented yet; the update covered trial completion milestones rather than efficacy or safety outcomes.
• The study tested whether the injectable neuroprotective candidate can improve stroke recovery while remaining tolerable, without disclosing performance details.
• The multi-center, randomized, double-blind, placebo-controlled trial enrolled 360 patients, starting September 2025, finishing enrollment March 2026, last patient out June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Micot Pharmaceutical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260724-12256178), on July 24, 2026, and is solely responsible for the information contained therein.